NCT06646341
EMVI as a Determinant of Metastasis in Colorectal Cancer
Recruiting · Not specified · Imperial College London · registry updated 2024-11-01
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years. This is normally due to spread of the cancer to other organs (called metastases). Much of the current research focuses on use of additional treatments such as radiotherapy and chemotherapy before or after surgery (adjuvant treatment). It is of vital importance that patients who would benefit from adjuvant treatment can be accurately identified. At the moment, the system used locally to do this places emphasis on the presence of affected lymph nodes (glands). This is because doctors believe that cancer spreads to other organs through the lymphatic system. However, recent studies have suggested that this is not the case. It is believed that cancer spreads to other organs through the blood stream rather than the lymph node system. This research will look at the genetic material in tumours and metastases as well as in areas of blood vessel invasion and lymph nodes. The analysis will allow us to build a 'family tree' of the tumour and allow us to map the pathway by which the tumour spreads....
Inclusion
- Are aged 16 years or over with colorectal cancer
- Colon / rectum has been surgically removed
- Distant metastases has been surgically removed
- Pre operative staging in the form of CT/MRI has been undertaken and images available for review
Exclusion
- Pathological complete response in the primary tumour
- Local resection of the primary tumour
- Inadequate quantity of tissue sample to perform analyses